UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 202

Sortiert nach

Regulation of IKKβ by miR-199a affects NF-κB activity in ovarian cancer cells

Oncogene, 2008-08, Vol.27 (34), p.4712-4723

2008

Link zum Volltext

Verfügbarkeit prüfen

Constitutive proteasomal degradation of TWIST-1 in epithelial-ovarian cancer stem cells impacts differentiation and metastatic potential

Oncogene, 2013-01, Vol.32 (1), p.39-49

2013

Link zum Volltext

Verfügbarkeit prüfen

Cancers take their Toll-the function and regulation of Toll-like receptors in cancer cells

Oncogene, 2008-01, Vol.27 (2), p.225-233

2008

Link zum Volltext

Verfügbarkeit prüfen

Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo

British journal of cancer, 2014-09, Vol.111 (9), p.1750-1756

2014

Link zum Volltext

Verfügbarkeit prüfen

In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma

British journal of cancer, 2010-01, Vol.102 (1), p.134-143

2010

Link zum Volltext

Verfügbarkeit prüfen

Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy

British journal of cancer, 2012-04, Vol.106 (9), p.1543-1550

2012

Link zum Volltext

Verfügbarkeit prüfen

Who chokes under pressure? The Big Five personality traits and decision-making under pressure

Personality and individual differences, 2015-02, Vol.74, p.22-28

2015

Link zum Volltext

Verfügbarkeit prüfen

Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunotherapy

British journal of cancer, 2013-07, Vol.109 (2), p.462-471

2013

Link zum Volltext

Verfügbarkeit prüfen

Her2 neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab

British journal of cancer, 2011-10, Vol.105 (8), p.1176-1182

2011

Link zum Volltext

Verfügbarkeit prüfen

Carcinosarcoma of the ovary

International journal of gynecological cancer, 2008, Vol.18 (1), p.22-29

2008

Link zum Volltext

Verfügbarkeit prüfen

Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo

Gynecologic oncology, 2015-12, Vol.139 (3), p.597-597

2015

Link zum Volltext

Verfügbarkeit prüfen

Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer

British journal of cancer, 2009-07, Vol.101 (2), p.335-341

2009

Link zum Volltext

Verfügbarkeit prüfen

Robotic Hysterectomy for a Large Myomatous Uterus

Journal of minimally invasive gynecology, 2015-03, Vol.22 (3), p.S64-S64

2015

Link zum Volltext

Verfügbarkeit prüfen

Abstract number 8: Platinum desensitization in patients with carboplatin hypersensitivity: A single-institution retrospective study

Gynecologic oncology, 2014-08, Vol.134 (2), p.432-433

2014

Link zum Volltext

Verfügbarkeit prüfen

Carcinosarcoma of the ovary

International journal of gynecological cancer, 2008-01, Vol.18 (1), p.22-29

2008

Link zum Volltext

Verfügbarkeit prüfen

Risk factors for omental metastasis in clinical stage I endometrial cancer: A meta-analysis

Gynecologic oncology, 2013-07, Vol.130 (1), p.e67-e67

2013

Link zum Volltext

Verfügbarkeit prüfen

Early Stage Uterine Serous Carcinoma: Does Surgical Approach Impact Survival?

Journal of minimally invasive gynecology, 2015-11, Vol.22 (6), p.S48-S49

2015

Link zum Volltext

Verfügbarkeit prüfen

Risk Factors Associated with Urinary Retention after Robotic-Assisted Laparoscopic Hysterectomy

Journal of minimally invasive gynecology, 2014-11, Vol.21 (6), p.S205-S205

2014

Link zum Volltext

Verfügbarkeit prüfen

hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma

British journal of cancer, 2010-09, Vol.103 (6), p.812-819

2010

Link zum Volltext

Verfügbarkeit prüfen

Class III beta-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel

Gynecologic oncology, 2013-07, Vol.130 (1), p.e124-e125

2013

Link zum Volltext

Verfügbarkeit prüfen

Ovarian versus uterine serous carcinomas: Clinicopathologic and miRNA analysis

Gynecologic oncology, 2013-07, Vol.130 (1), p.e92-e92

2013

Link zum Volltext

Verfügbarkeit prüfen

Institutional review of primary lymphoma of the female genital tract: A 32-year experience

Gynecologic oncology, 2013-07, Vol.130 (1), p.e152-e153

2013

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant Carboplatin/Paclitaxel and Vaginal Brachytherapy for Locally Advanced Endometrial Cancer

International journal of radiation oncology, biology, physics, 2012-11, Vol.84 (3), p.S447-S448

2012

Link zum Volltext

Verfügbarkeit prüfen

7 Gy x 2 – An Effective Brachytherapy Regimen for Stage I-II Uterine Papillary Serous Carcinoma

International journal of radiation oncology, biology, physics, 2013-10, Vol.87 (2), p.S420-S421

2013

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 202

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(194)
Mit Volltextzugriff
(191)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(111)
Life Sciences & Biomedicine
(104)
Female
(83)
Humans
(79)
Oncology
(69)
Animals
(49)
Middle Aged
(46)
Obstetrics And Gynecology
(41)
Aged
(38)
Obstetrics & Gynecology
(35)
Tumors
(35)
Cell Line, Tumor
(33)
Mice
(30)
Adult
(29)
Ovarian Cancer
(25)
Hematology, Oncology And Palliative Medicine
(22)
Biological And Medical Sciences
(21)
Flow Cytometry
(21)
Medical Sciences
(19)
Surgery
(19)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793)

Regulation of IKKβ by miR-199a affects NF-κB activity in ovarian cancer cells

Constitutive proteasomal degradation of TWIST-1 in epithelial-ovarian cancer stem cells impacts differentiation and metastatic potential

Cancers take their Toll-the function and regulation of Toll-like receptors in cancer cells

Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo

In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma

Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy

Who chokes under pressure? The Big Five personality traits and decision-making under pressure

Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunotherapy

Her2 neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab

Carcinosarcoma of the ovary

Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo

Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer

Robotic Hysterectomy for a Large Myomatous Uterus

Abstract number 8: Platinum desensitization in patients with carboplatin hypersensitivity: A single-institution retrospective study

Carcinosarcoma of the ovary

Risk factors for omental metastasis in clinical stage I endometrial cancer: A meta-analysis

Early Stage Uterine Serous Carcinoma: Does Surgical Approach Impact Survival?

Risk Factors Associated with Urinary Retention after Robotic-Assisted Laparoscopic Hysterectomy

hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma

Class III beta-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel

Ovarian versus uterine serous carcinomas: Clinicopathologic and miRNA analysis

Institutional review of primary lymphoma of the female genital tract: A 32-year experience

Adjuvant Carboplatin/Paclitaxel and Vaginal Brachytherapy for Locally Advanced Endometrial Cancer

7 Gy x 2 – An Effective Brachytherapy Regimen for Stage I-II Uterine Papillary Serous Carcinoma

Suchergebnisse filtern